Epilepsy belongs to the most common and debilitating neurological disorders with multifactorial pathophysiology and a high level of drug resistance. Therefore, with the aim of searching for new, more effective, and/or safer therapeutics, we discovered a focused series of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant properties. We applied an optimized coupling reaction yielding several hybrid compounds that showed broad-spectrum activity in widely accepted animal seizure models, namely, the maximal electroshock (MES) test and the psychomotor 6 Hz (32 mA) seizure model in mice. The most potent anticonvulsant activity and favorable safety profile was demonstrated for compound (median effective dose (ED) MES = 45.6 mg/kg, ED 6 Hz (32 mA) = 39.5 mg/kg, median toxic dose (TD) (rotarod test) = 162.4 mg/kg). Anticonvulsant drugs often show activity in pain models, and compound was also proven effective in the formalin test of tonic pain, the capsaicin-induced pain model, and the oxaliplatin (OXPT)-induced neuropathic pain model in mice. Our studies showed that the most plausible mechanism of action of involves inhibition of calcium currents mediated by Cav (L-type) channels. Importantly, revealed high metabolic stability on human liver microsomes, negligible hepatotoxicity, and relatively weak inhibition of CYP3A4, CYP2D6, and CYP2C9 isoforms of cytochrome P450, compared to reference compounds. The promising in vivo activity profile and drug-like properties of compound make it an interesting candidate for further preclinical development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699745 | PMC |
http://dx.doi.org/10.3390/ijms21228780 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!